NJ · State regulatory reference

New Jersey.

Moderate

Telemedicine practice runs under the Telemedicine and Telehealth Act (N.J.S.A. 45:1-61 et seq.); N.J.S.A. 45:1-62 requires a proper provider-patient relationship, bars prescribing 'based solely on the responses provided in an online static questionnaire,' and holds telemedicine to the in-person standard of care. Compounding under N.J.A.C. 13:39 incorporates USP <795>/<797>/<800> by reference, with a Prohibited Compounding rule at 13:39-11.25. The State Board of Pharmacy's Statement Concerning Semaglutide Compounding (2023) restricts GLP-1 compounding to narrow 503A circumstances, but that restates federal law as guidance rather than a distinctive state rule, and no documented enforcement pattern against peptide/GLP-1 or telehealth-wellness prescribers was found.

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

New Jersey Medical Board

https://www.njconsumeraffairs.gov/bme/ ↗

Pharmacy board

New Jersey Board of Pharmacy

https://www.njconsumeraffairs.gov/pha/ ↗

TPC notes

Telehealth

N.J.S.A. 45:1-62 lets a provider establish the required relationship via real-time two-way audio-video (asynchronous store-and-forward if the standard of care allows), but prohibits prescribing based solely on a static online questionnaire. Schedule II telehealth prescribing now requires an in-person visit; non-controlled peptides and GLP-1s are unaffected.

Compounding

N.J.A.C. 13:39-11/11A adopt USP <795>/<797>/<800> by reference with a 48-hour contamination-reporting duty. The Board's semaglutide statement (citing 13:39-11.25 and FDCA § 503A(b)) says pharmacies generally may not compound semaglutide except in narrow circumstances and may not use salt forms or non-FDA-registered API.

Sources